BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32767816)

  • 1. Analysis of CRISPR-Cas9 screens identifies genetic dependencies in melanoma.
    Christodoulou E; Rashid M; Pacini C; Droop A; Robertson H; Groningen TV; Teunisse AFAS; Iorio F; Jochemsen AG; Adams DJ; Doorn RV
    Pigment Cell Melanoma Res; 2021 Jan; 34(1):122-131. PubMed ID: 32767816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.
    Ito T; Young MJ; Li R; Jain S; Wernitznig A; Krill-Burger JM; Lemke CT; Monducci D; Rodriguez DJ; Chang L; Dutta S; Pal D; Paolella BR; Rothberg MV; Root DE; Johannessen CM; Parida L; Getz G; Vazquez F; Doench JG; Zamanighomi M; Sellers WR
    Nat Genet; 2021 Dec; 53(12):1664-1672. PubMed ID: 34857952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DUSP4 Inactivation Leads to Reduced Extracellular Signal‒Regulated Kinase Activity through Upregulation of DUSP6 in Melanoma Cells.
    Kamada H; Yasuhira S; Shibazaki M; Amano H; Maesawa C
    J Invest Dermatol; 2022 Sep; 142(9):2499-2507.e6. PubMed ID: 35189148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
    Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
    Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
    [No Abstract]   [Full Text] [Related]  

  • 5. Investigating the Role of DUSP4 in Uveal Melanoma.
    Aughton K; Sabat-Pospiech D; Barlow S; Coupland SE; Kalirai H
    Transl Vis Sci Technol; 2022 Dec; 11(12):13. PubMed ID: 36576731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DUSP4 is involved in the enhanced proliferation and survival of DUSP4-overexpressing cancer cells.
    Ratsada P; Hijiya N; Hidano S; Tsukamoto Y; Nakada C; Uchida T; Kobayashi T; Moriyama M
    Biochem Biophys Res Commun; 2020 Jul; 528(3):586-593. PubMed ID: 32505357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.
    Mazumdar A; Poage GM; Shepherd J; Tsimelzon A; Hartman ZC; Den Hollander P; Hill J; Zhang Y; Chang J; Hilsenbeck SG; Fuqua S; Kent Osborne C; Mills GB; Brown PH
    Breast Cancer Res Treat; 2016 Aug; 158(3):441-54. PubMed ID: 27393618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation.
    Jiang C; Trudeau SJ; Cheong TC; Guo R; Teng M; Wang LW; Wang Z; Pighi C; Gautier-Courteille C; Ma Y; Jiang S; Wang C; Zhao B; Paillard L; Doench JG; Chiarle R; Gewurz BE
    Cell Rep; 2019 Jul; 28(5):1307-1322.e8. PubMed ID: 31365872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
    Gröschl B; Bettstetter M; Giedl C; Woenckhaus M; Edmonston T; Hofstädter F; Dietmaier W
    Int J Cancer; 2013 Apr; 132(7):1537-46. PubMed ID: 22965873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor-α-mediated suppression of dual-specificity phosphatase 4: crosstalk between NFκB and MAPK regulates endothelial cell survival.
    Kao DD; Oldebeken SR; Rai A; Lubos E; Leopold JA; Loscalzo J; Handy DE
    Mol Cell Biochem; 2013 Oct; 382(1-2):153-62. PubMed ID: 23812841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.
    Gupta R; Bugide S; Wang B; Green MR; Johnson DB; Wajapeyee N
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4583-4591. PubMed ID: 30782837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of dual-specificity phosphatase 4 enhances cell proliferation and invasiveness in colorectal carcinomas.
    Ichimanda M; Hijiya N; Tsukamoto Y; Uchida T; Nakada C; Akagi T; Etoh T; Iha H; Inomata M; Takekawa M; Moriyama M
    Cancer Sci; 2018 Jan; 109(1):250-258. PubMed ID: 29150975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DUSP4 appears to be a highly localized endogenous inhibitor of epileptic signaling in human neocortex.
    Kirchner A; Bagla S; Dachet F; Loeb JA
    Neurobiol Dis; 2020 Nov; 145():105073. PubMed ID: 32890776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF.
    Gutierrez-Prat N; Zuberer HL; Mangano L; Karimaddini Z; Wolf L; Tyanova S; Wellinger LC; Marbach D; Griesser V; Pettazzoni P; Bischoff JR; Rohle D; Palladino C; Vivanco I
    Life Sci Alliance; 2022 Sep; 5(9):. PubMed ID: 35580987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
    Jung HH; Lee SH; Kim JY; Ahn JS; Park YH; Im YH
    Sci Rep; 2016 Sep; 6():33035. PubMed ID: 27604655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
    Balko JM; Cook RS; Vaught DB; Kuba MG; Miller TW; Bhola NE; Sanders ME; Granja-Ingram NM; Smith JJ; Meszoely IM; Salter J; Dowsett M; Stemke-Hale K; González-Angulo AM; Mills GB; Pinto JA; Gómez HL; Arteaga CL
    Nat Med; 2012 Jul; 18(7):1052-9. PubMed ID: 22683778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.
    Balko JM; Schwarz LJ; Bhola NE; Kurupi R; Owens P; Miller TW; Gómez H; Cook RS; Arteaga CL
    Cancer Res; 2013 Oct; 73(20):6346-58. PubMed ID: 23966295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
    Shi Y; Ma IT; Patel RH; Shang X; Chen Z; Zhao Y; Cheng J; Fan Y; Rojas Y; Barbieri E; Chen Z; Yu Y; Jin J; Kim ES; Shohet JM; Vasudevan SA; Yang J
    Cell Death Dis; 2015 Aug; 6(8):e1841. PubMed ID: 26247726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting.
    Iorio F; Behan FM; Gonçalves E; Bhosle SG; Chen E; Shepherd R; Beaver C; Ansari R; Pooley R; Wilkinson P; Harper S; Butler AP; Stronach EA; Saez-Rodriguez J; Yusa K; Garnett MJ
    BMC Genomics; 2018 Aug; 19(1):604. PubMed ID: 30103702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening.
    Kiessling MK; Schuierer S; Stertz S; Beibel M; Bergling S; Knehr J; Carbone W; de Vallière C; Tchinda J; Bouwmeester T; Seuwen K; Rogler G; Roma G
    BMC Genomics; 2016 Sep; 17(1):723. PubMed ID: 27613601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.